<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Pramlintide, a human amylin analogue, is a potential new adjunctive therapy to insulin for patients with type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> and insulin-using patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>Early clinical trials have shown a transient increased risk of <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> in some patients at the time of initiating pramlintide therapy </plain></SENT>
<SENT sid="2" pm="."><plain>This may be the result of combining the postprandial <z:chebi fb="105" ids="17234">glucose</z:chebi>, lowering effect of pramlintide with the existing hypoglycaemic potential of insulin without appropriate adjustment of insulin doses </plain></SENT>
<SENT sid="3" pm="."><plain>However, the possibility that pramlintide may exert an independent detrimental effect on the physiological responses to insulin-induced <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> needs to be excluded </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: We conducted three separate randomized, placebo-controlled studies in patients with type 1 <z:mp ids='MP_0002055'>diabetes</z:mp> treated with adjunctive pramlintide </plain></SENT>
<SENT sid="5" pm="."><plain>These studies utilized pramlintide at high doses (either 0.1-1 mg pramlintide daily or 0.1-0.8 mg pramlintide four times a day for 5 or 6 days) as well as doses closer to those anticipated for therapeutic usage (30, 100 or 300 microg three times daily for 14 days), and examined the hormonal, metabolic and symptomatic responses to an insulin-infusion hypoglycaemic challenge conducted at baseline and after days of therapy </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS AND CONCLUSION: Pramlintide had no effect on the counter-regulatory hormonal, metabolic and symptomatic responses to <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>These findings demonstrated that pramlintide, when used as adjunctive therapy to insulin in patients with type 1 <z:mp ids='MP_0002055'>diabetes</z:mp>, has no independent effect on the response to <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e> </plain></SENT>
</text></document>